Racura Oncology Ltd
1.01
EUR
0.00
(0.00%)
ISIN
AU000000RAC3
Return %
Stock
S&P 500
1Y
-52.36
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Daniel Tillett
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Gateway, 1 Macquarie Place Sydney NSW Australia 2000
- IPO Date
- Jul 13, 2016
- Website
- raceoncology.com
- Similar Companies
- Business
- Race Oncology Limited Race Oncology Limited (ASX:RAC) is an Australia-based clinical-stage biopharmaceutical company focused on developing innovative oncology therapies to address unmet needs in cancer treatment, particularly through its lead asset RC220 bisantrene, a proprietary reformulated version of the small molecule chemotherapeutic bisantrene that demonstrates anticancer activity with reduced cardiotoxicity compared to anthracyclines such as doxorubicin; the company advances RC220 in combination therapies for solid tumors, acute myeloid leukemia, and non-small cell lung cancer, while investigating its effects on the m6A RNA pathway as a potent inhibitor of FTO protein to target cancer-driving dysregulation. Race Oncology Limited operates primarily in the biotechnology sector, targeting adult and pediatric cancer patients across multiple indications with a pipeline emphasizing cardioprotection, enhanced efficacy in anthracycline combinations, and resistance-overcoming mechanisms in EGFR-mutated NSCLC. Founded in 2011 and headquartered in Sydney, Australia, at Level 36, Gateway, 1 Macquarie Place, the company collaborates with leading institutions including Astex, City of Hope, MD Anderson Cancer Center, Sheba Medical Center, UNC School of Medicine, University of Wollongong, and University of Newcastle. Recent developments include securing Human Research Ethics Committee approval in November 2025 from St Vincent’s Hospital Melbourne for a Phase 1a/b trial (HARNESS-1) of RC220 combined with AstraZeneca’s osimertinib in EGFR-mutated NSCLC patients post-TKI resistance, with patient enrollment slated for late 2025 or early 2026 at Monash Health and additional Australian sites; advancing a Phase 1a/b solid tumor trial with doxorubicin; appointing George Clinical for trial support; filing patents for bisantrene’s single active isomer to extend exclusivity potentially to 2045; and issuing new securities alongside director option acquisitions to bolster its clinical and commercialization strategy.
Company News
Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
Daniel Tillett Purchases 100,000 Shares of Race Oncology (ASX:RAC) Stock
October inflation, jobs reports cancelled due to US government shutdown
Fed may skip December cut but leave door open for January, Deutsche Bank analysts say
Race Oncology launches new clinical programs in AML and lung cancer
Pensana shares up as it launches new drill and testing plans for Angola rare-earth project